According to FutureWise analysis, the market for biosimilar therapeutic peptides in 2025 is US$ 3.92 billion and is expected to reach US$ 17.33 billion by 2033 at a CAGR of 20.42%.
Therapeutic peptides, consisting of short chains of 2 to 50 amino acids, are designed to offer high specificity and potency in the treatment of various conditions, including diabetes, cancer, osteoporosis, and cardiovascular diseases. These peptides can be chemically synthesized or produced through recombinant methods, providing several advantages over larger biologics, such as enhanced stability, reduced immunogenicity, and precise targeting capabilities. Notable examples of therapeutic peptides include insulin, introduced in 1921, glucagon-like peptide-1 (GLP-1) agonists such as exenatide and liraglutide for managing type 2 diabetes, and teriparatide for the treatment of osteoporosis.
Biosimilar therapeutic peptides are versions of originator peptides whose patents have expired. They are engineered to closely match the reference product in terms of structure, purity, bioactivity, and clinical effectiveness, often at a lower cost. Unlike small-molecule generics, biosimilars of peptides must demonstrate analytical similarity due to potential variations in synthesis methods, impurities, or folding of the peptides. Regulatory pathways, such as those established by the European Medicines Agency (EMA) since 2006 and the U.S. Food and Drug Administration (FDA) through the 505(b)(2) or Abbreviated New Drug Application (ANDA) for certain peptides, focus on comparative physicochemical characterization (using techniques like HPLC, mass spectrometry, and NMR) and bioassays.
The development process includes solid-phase peptide synthesis (SPPS) or hybrid recombinant-chemical methods, followed by thorough purification to manage truncation, deamidation, or oxidation variations. For example, the biosimilar glatiramer acetate, used in the treatment of multiple sclerosis, needs to replicate the originator’s intricate mixture of random polypeptides. Meanwhile, biosimilar teriparatide must ensure it mirrors the identical 34-amino-acid sequence and maintains comparable affinity for parathyroid hormone receptors. Clinical studies typically confirm pharmacokinetic equivalence and immunogenic similarity, and extrapolation across different indications is permitted when the mechanisms of action align.
FutureWise Market Research has published a report that provides an insightful analysis of Biosimilar Therapeutic Peptides Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10995&type=requestsample
Biosimilar Therapeutic Peptides Market Segmentation:
By Route of Administration
• Parenteral Route
• Transdermal Route
• Others

By Application
• Cancer
• Cardiovascular
• Central Nervous Systems
• Metabolic Disorders
• Infection
• Hematological Disorders
• Gastrointestinal Disorders
• Dermatology
• Respiratory Disorders

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Biosimilar Therapeutic Peptides Market :
• Eli Lilly
• Sanofi
• Takeda Pharmaceuticals
• Teva Pharmaceuticals
• Pfizer Inc.
• Amgen Inc.
• AstraZeneca PLC
• GlaxoSmithKline (GSK)
• Novartis AG
• Novo Nordisk A/S
• Ipsen S.A
• MerckCo. Inc.
• F. Hoffmann-La Roche Ltd.
• Bachem Holding AG
• CordenPharma International
• BioPartners
• Hyperion Therapeutics
• PeptiDream
• Bachem Holding AG
• Lonza Inc.
• Bristol-Myers Squibb(BMS)
• PolyPeptide Laboratories

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10995&license=multi




**Objectives of this Study: **
1. To provide a comprehensive analysis of the Biosimilar Therapeutic Peptides Market By Route of Administration, By Application and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com